Recent studies reported that GLP-1 increases the phosphorylation of AMPK in hepatocytes and reverses hepatic steatosis by stimulating fatty acid oxidation [8,31,32]
Genetic approaches to manipulate hepatic oxalate metabolism included generation of Agxt -/- mice using CRIPSR/Cas9 and hepatocyte-specific overexpression of AGXT using AAV8-TBG-AGXT during diet-induced MASH
using GLP-1s could reach 25 million by 2030 (rising from 10 million in 2025)
Provider and prescriber insights: Identify prescribing patterns, top prescribers, and geographic variation in clinical decision-making
Improved lab markers : Beyond weight, we typically see improvements in inflammatory markers, cholesterol values, and liver function testsreducing long-term health risks
stimulate or agonize insulin production and suppress appetite)